Gan & Lee Pharmaceuticals

Name: Gan & Lee Pharmaceuticals
Address: 通州区漷县镇南凤西一路8号, Beijing, CN
Telephone: +861056965000

Home
China
Beijing
Gan & Lee Pharmaceuticals

Founded in 1998, Gan&Lee Pharmaceuticals is a high-tech biopharmaceutical China-based company. Curren

26/05/2026

Our 2025 ESG Report is now live.

At Gan & Lee Pharmaceuticals, our ESG strategy — Patients First, Medicine for Good. — continues to guide how we innovate, operate and create long-term value responsibly.

In 2025, we continued advancing our commitments through:

🛡 Strengthening anti-corruption and ethical business practices
💙 Enhancing product quality, safety and patient trust
🔬 Driving innovation in diabetes and metabolic disease therapies
🌍 Expanding access to affordable and high-quality healthcare
🌱 Advancing green development and sustainable operations

As we continue our journey toward becoming a leading global biopharmaceutical company, we believe the long-term value of a healthcare company goes beyond business growth — it lies in improving human health and well-being through responsible and sustainable development.

Read the full 2025 ESG Report: https://www.ganlee.com/ESG_publicity.html

20/05/2026

Discover the Next Frontier at Booth #1001

The countdown to is officially underway! We cordially invite all healthcare professionals, researchers, and industry partners to visit us at Booth #1001 in New Orleans.

Why visit us?

🔬 In-depth Pipeline Insights: Connect with our scientific team to discuss the latest progress of GZR4, Bofanglutide and GZR102.

📊 Clinical Data Updates: Discuss our cutting-edge clinical research findings directly with our experts.

🤝 Global Collaboration Opportunities: Explore joint initiatives to enhance patient care worldwide.

Let’s connect, cooperate and advance the next frontier of medical innovation. We look forward to meeting you in New Orleans!

19/05/2026

We are thrilled to announce that Gan & Lee will be presenting our latest clinical trial data at the upcoming 86th American Diabetes Association Scientific Sessions.

Learn More Information: https://www.ganlee.com/detail/846.html

Science is driven by evidence, and we can't wait to share the evidence that could redefine treatment standards. Mark your calendars for June 7th—the wait for innovation is almost over.

Location: The Poster Hall (Halls D-E) of the Ernest N. Morial Convention Center
Presentation Time: June 7, 2026, 12:30–1:30 PM (CDT)

15/05/2026

Exciting news! The European Commission (EC) has granted marketing authorization for Gan & Lee’s independently developed insulin aspart and lispro injections.

Rooted in our mission to deliver high-quality medicines and services to improve lives worldwide, we are proud to expand our global footprint in diabetes care.

Learn more in the press release here: https://www.ganlee.com/detail/845.html

24/04/2026

Gan & Lee's Eurasia team recently met with Dr. Hilal Al Sabti, Oman’s Minister of Health, to discuss biopharma localization and chronic disease management.

We are proud to be the first Chinese pharmaceutical company officially received by the Minister. Together, we’re bridging innovative healthcare solutions between China and the Middle East.

Read more: https://www.ganlee.com/detail/842.htm

09/04/2026

News from Brazil! 🇧🇷✨

Our insulin aspart and insulin lispro drug substances have officially received ANVISA GMP certification!

With this certification, all three of our core insulin drug substances—glargine, aspart, and Lispro—have now passed ANVISA's GMP inspection. This transition from a single long-acting product to a comprehensive portfolio of both long-acting and rapid-acting insulins marks a critical step in our mission to provide high-quality, accessible diabetes care across Latin America.

Learn More: https://www.ganlee.com/detail/840.html

02/04/2026

At Gan & Lee, we are focused on advancing innovative therapies for patients.We are currently developing GLR2037, an AR PROTAC molecule, as part of our research in precision oncology.
This targeted approach has the potential to address a critical need in prostate cancer, especially for patients with limited treatment options.
We continue to drive scientific innovation and aim to bring meaningful therapeutic value to patients around the world.✨
Read more: https://www.ganlee.com.cn/detail/1697.html

19/03/2026

We are honored to receive the "Most Innovative Company of the Year" award at BioChina 2026. This award is more than just an accolade; it is a reflection of Gan & Lee's dedication to quality, precision, and patient-centric innovation in every step of our process.

We appreciate the recognition from the industry as we continue our work in developing biopharmaceutical therapies for patients globally.

Onwards and upwards. ✨

09/03/2026

Big news at Gan & Lee! We are thrilled to welcome Qi WANG as our new Executive Vice President and Chief Financial Officer. Qi brings extensive experience in healthcare finance and capital markets, having played a key role in our IPO and subsequent financing. He will lead our financial strategy, digital transformation, and work alongside our CMO and CSO to accelerate our global innovation journey. Join us in congratulating Qi on his new role!

08/03/2026

She believed she could, so she did.

Happy International Women's Day to all the Sheroes.

04/03/2026

This World Obesity Day, we join the global movement for "8 Billion Reasons to Act on Obesity".
Obesity is a complex chronic disease closely linked to metabolic health. It requires compassion, understanding, and support.💙
Together, let’s choose health, stand in solidarity, and create positive change for people around the world.🌍

Address

通州区漷县镇南凤西一路8号
Beijing

Telephone

+861056965000

Website

http://www.ganlee.com/

Alerts

Be the first to know and let us send you an email when Gan & Lee Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Gan & Lee Pharmaceuticals:

Shortcuts

Want your business to be the top-listed Engineering Company in Beijing?